PROMETIC BIOSCIENCES ACHIEVES SECOND MILESTONE OF LICENSE.ProMetic Life Sciences, Montreal, (PLI PLI Practising Law Institute PLI Professional Liability Insurance PLI Programming Language Interface (Verilog programming language) PLI Partido Liberal Independiente (Independent Liberal Party, Nicaragua) :TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension ) has announced that its subsidiary ProMetic BioSciences Limited (ProMetic) has achieved the second milestone of its License Agreement with AM-Pharma B.V. ProMetic's technology has been licensed to AM-Pharma for use in connection with Alkaline Phosphatase, a proprietary product being developed by AM-Pharma for the treatment of sepsis and septic shock. The objective of this second milestone was to achieve AM-Pharma's performance criteria. The last two milestones relate to the scale-up, commercialization and development of an integrated process for alkaline phosphatase purification using ProMetic technology. "This is yet another demonstration of ProMetic's ability to develop high- performance purification materials derived from its Mimetic Ligand(TM) platform technology and one of several new affinity products we have developed for our commercial partners over the last 12 months", said Dr. Steve Burton, executive vice president and CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. . AM-Pharma's product has been tested successfully in Phase I and Phase IIa clinical trials. A more elaborate Phase II clinical study in two university- based Dutch Intensive Care Units will be initiated shortly. About the License Agreement The License Agreement includes milestone payments to ProMetic representing $700,000 CDN (Content Delivery Network) A system of distributed content on a large intranet or the public Internet in which copies of content are replicated and cached throughout the network. . Prometic will also receive royalties in relation to the sale of alkaline phosphatase manufactured using ProMetic's technology and revenues from the supply of Mimetic Ligand(TM). "Sepsis is a major medical concern which accounts for millions of dollars annually. ProMetic's technology will help address this health problem by providing pure alkaline phosphatase, which has shown great promise as a therapeutic. We are very pleased with this agreement because it contributes to ProMetic's near-term revenue stream based on its enabling technology and provides ProMetic with significant upside potential from royalties on future product sales" commented Pierre Laurin, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ProMetic. About Sepsis Sepsis is a major challenge in medicine. It is a major cause of morbidity and mortality Morbidity and Mortality can refer to:
the action of a horse when it refuses to obey a command to which it usually responds. See also jibbing. , 2000), particularly in elderly, immuno-compromised and critically ill patients. In the US alone, it is estimated that more than 700,000 cases of severe sepsis, hypoperfusion or shock occur per year (Linde-Zwirble, 1999), which when extrapolated to a global population represents several million cases of severe sepsis annually worldwide. Data also shows that sepsis is the leading cause of death in non-coronary ICU ICU intensive care unit. ICU abbr. intensive care unit ICU see intensive care unit. ICU patients (Sands 1997), and data collected by the Centers for Disease Control in 1998 shows that it was the 11th leading cause of death overall. The CDC See Control Data, century date change and Back Orifice. CDC - Control Data Corporation warned that the incidence was increasing, citing the aging US population and the increased prevalence of human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ) infection as contributing factors. Also, the widespread use of broad-spectrum antibiotics has increased the rates of both antibiotic resistant and nosocomial infections of sepsis. A recent study published in Crit. Care. Med. (2001) Vol. 29, No.7, clearly demonstrates the ongoing increase in instances of these conditions that are frequently fatal and expensive for the healthcare system. About ProMetic ProMetic Life Sciences Inc. is an international biopharmaceutical company with headquarters in Montreal (Quebec), and additional facilities in the UK and the USA. ProMetic specializes in the research, development, manufacture and marketing of a variety of commercial applications from its proprietary platform technologies, which are used in the development of therapeutics, large-scale purification of biologics and the elimination of pathogens/viruses. About AM-Pharma AM-Pharma is focused on the development of novel pharmaceutical compounds, derived from the innate human immune system. The resulting products are intended for the treatment of patients suffering from a variety of serious infectious diseases. Specifically, the company operates in the segments of LPS- mediated diseases and infections of fungal and bacterial origin, offering products that address unmet medical needs. The current lead compound, recombinant alkaline phosphatase, is developed in collaboration with Biozyme Laboratories Ltd. (Blaenavon, UK), a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Theratase plc (London, UK), a founding investor in AM-Pharma Holding. For more information, call 514/341-2115 or visit http://www.prometic.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion